

## TABLE OF CONTENTS

	<b>Page</b>
TABLE OF CONTENTS	i
LIST OF TABLES	iii
LIST OF FIGURES	v
ABBREVIATIONS	viii
INTRODUCTION	1
LITERATURE REVIEW	13
MATERIAL AND METHODS	21
Methodologies	21
Pharmacophore searching	21
Molecular docking	22
FlexX	23
GOLD	28
Surflex	34
Computational details of calculations	39
CHAPTER I: Virtual Screening of K103N and Y181C HIV-1 Reverse Transcriptase Mutants Based on Nevirapine and Some NNRTIs	39
CHAPTER II: Design of Nevirapine Derivatives Insensitive to the K103N and Y181C HIV-1 Reverse Transcriptase Mutants	45
RESULTS AND DISCUSSION	50
CHAPTER I: Virtual Screening of K103N and Y181C HIV-1 Reverse Transcriptase Mutants Based on Nevirapine and Some NNRTIs	50
Validation of the docking method	51
Docking of other NNRTIs	52
Pharmacophore database searching	54
Database searching	58

**TABLE OF CONTENTS (cont'd)**

	<b>Page</b>
Classification of the hits	58
Test for HIV-1 inhibition	71
CHAPTER II: Design of Nevirapine Derivatives Insensitive to the K103N and Y181C HIV-1 Reverse Transcriptase Mutants	73
Docking of nevirapine derivatives and post docking analysis	73
Calculation of interaction energy	83
CONCLUSIONS	89
LITERATURE CITED	91
APPENDIX	108
Appendix A: Theoretical background	109
Appendix B: Ultrasensitive Reverse Transcriptase Assay	133
Appendix C: Oral presentation and poster contribution to conferences	135
Appendix D: Publications	139

**LIST OF TABLES**

<b>Table</b>		<b>Page</b>
1	Binding affinities of nevirapine against wild type and mutant types RT	10
2	Docking algorithm and scoring functions of the docking tools	23
3	Advantages and disadvantages of FlexX program	27
4	Advantages and disadvantages of GOLD program	33
5	Advantages and disadvantages of Surflex program	38
6	Contents of “Bioinfo” database	41
7	Structures of designed nevirapine derivatives, using a combinatorial library design approach	48
8	Rmsd (Å) of the docked pose from the X-ray pose of nevirapine and PNU-142721 by using FlexX, GOLD and Surflex methods	51
9	Numbers of hits with GoldScore higher than 45 and 50 for K103N and Y181C protein mutants	58
10	Number and structure of selected compounds from procedure1, procedure2 and common compounds to both procedures for K103N protein mutant	59
11	Number and structure of selected compounds from procedure1, procedure2 and common compounds to both procedures	65
12	Number of selected compounds from procedure1, procedure2 and common compounds to both procedures for Y181C protein mutant	68
13	Testing results of wild-type, K103N and Y181C HIV-1 inhibition of the selected compounds by using enzyme assay	72
14	GoldScore of docked nevirapine derivatives into the both protein mutants	74
15	Selected which have H-bonding with N103 or C181 for K103N and Y181C mutants, respectively and percentage of their surface buried upon binding higher than 80%	79
16	Interaction energies between N103 and 25 selected compounds of K103N mutant	85

**LIST OF TABLES (cont'd)**

<b>Table</b>		<b>Page</b>
17	Interaction energy between C181 and selected compounds of Y181C mutant	87

## LIST OF FIGURES

<b>Figure</b>		<b>Page</b>
1	Structure of HIV-1 RT (taken from PDB entry 1vrt)	7
2	a). Structures of nucleoside reverse transcriptase inhibitors (NRTIs)	
	b). Mechanism of action of AZT interfering with the HIV-1 RT reaction	8
3	Structures of non-nucleoside reverse transcriptase inhibitors (NNRTIs)	9
4	Binding pocket of wild-type HIV-1 RT complex with nevirapine (taken from PDB entry 1vrt)	10
5	Binding pocket of wild-type, K103N (a) and Y181C (b) HIV-1 RT complex with nevirapine. The electrostatic potential of nevirapine and the mutant residues are shown on the van der Waals surface as red for negative and blue for positive values	11
6	Orientation of PNU-142721 (displayed in ball and stick model) in the K103N binding pocket (taken from PDB code 1ikx (Lindberg, <i>et al.</i> , 2002))	12
7	Models of the compound <i>N</i> -[2-(1-piperidinoethyl)]- <i>N'</i> -[2-(5-bromopyridyl)]-thiourea (color coded by atom type) and compound <i>N</i> -[2-(2,5-dimethoxyphenylethyl)]- <i>N'</i> -[2-(5-bromopyridyl)]-thiourea (in blue) (HI-236) in the NNI binding site of HIV RT, positioned by a docking procedure. Wing 1 and Wing 2 represent two different regions of the NNI binding site	17
8	3D pharmacophore model derived from a series of NNRTIs	22
9	Example of carbonyl group's interaction model in FlexX program	
	a). Interaction center and surface of the carbonyl group	
	b). Spheres, cones, capped cones and spherical rectangles interaction surfaces	24

### LIST OF FIGURES (cont'd)

<b>Figure</b>		<b>Page</b>
10	Fragment placement algorithm in FlexX	25
11	Protomol for streptavidin (1stp) compared with the native pose of biotin (green). The protomol consists of CH <sub>4</sub> (hydrogens not shown), N-H, and C=O molecular fragments	34
12	Docking and scoring procedures of Surflex program	35
13	Structures of NNRTIs	40
14	Structure of fragments, used in the design of nevirapine derivatives	46
15	Virtual screening procedure	50
16	Conformations of docked NNRTIs; a). Docked conformations of nevirapine (yellow), efavirenz (blue) and PNU-142721 (pink) in the K103N binding pocket (PDB code 1fkp) b). Docked conformations of docked PNU-142721 (blue) compared with the orientation of X-ray pose (yellow) in the K103N binding pocket (PDB code 1ikx) c). Docked conformations of nevirapine (yellow), efavirenz (blue) and 8-Cl TIBO (green) in the Y181C binding pocket (PDB code 1jlb)	53
17	Features and constraints of all pharmacophore models	56
18	Orientation of selected nevirapine derivatives in K103N binding pocket (side view (a) and top view (b))	81
19	Orientation of selected nevirapine derivatives in Y181C binding pocket (side view (a) and top view (b))	82
20	Orientation of selected nevirapine derivatives (Cpd1 (a), Cpd3 (b), and Cpd2 (c) in atom-type color) having H-bonding with backbone N103 compared with N103 and nevirapine (green color)	86

**LIST OF FIGURES (cont'd)**

<b>Figure</b>		<b>Page</b>
21	Orientation of selected nevirapine derivatives (Cpd9 (a) and Cpd20 (b) in atom-type color) having H-bonding with sidechain N103 compared with N103 and nevirapine (green color)	86
22	Orientation of selected nevirapine derivatives (Cpd26 (a) and Cpd27 (b) in atom-type color) having H-bonding with C181 compared with C181 and nevirapine (green color)	88
<b>Appendix Figure</b>		
A1	A common scheme for solving the Roothaan-Hall equations by using SCF procedure	122
A2	DOCK algorithm. Atoms are matched to a binding site represented as a collection of overlapping spheres	128
A3	Genetic algorithm (GA) procedure	130

## ABBREVIATIONS

8-Cl TIBO	=	(+)-(S)-4,5,6,7-Tetrahydro-8-chloro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1- <i>jk</i> ][1,4]benzodiazepine-2(1 <i>H</i> )-thione
9-Cl TIBO	=	9-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4,5,1- <i>jk</i> )(1,4)benzodiazepine-2-(1 <i>H</i> )-thione
3D-pharmacophore	=	Three-dimensional pharmacophore
3D-QSAR	=	Three-dimensional quantitative structure-activity Relationships
AIDS	=	Acquired immunodeficiency syndrome
Ala (A)	=	Alanine
AMV	=	Avian Myeloblastosis Virus
Asn (N)	=	Asparagine
Asp (D)	=	Aspartic acid
AZT	=	3'-azido-2',3'-dideoxythymidine, azidothymidine
CI	=	Configuration Interaction
Cys (C)	=	Cysteine
ddC	=	2',3'-dideoxycytidine, Zalcitabine
ddI	=	2',3'-dideoxyinosine, Didanosine
DFT	=	Density functional theory
DNA	=	Deoxyribonucleic acid
dNTP	=	Deoxyribonucleotide triphosphate
DTT	=	Dithiothreitol
Efavirenz	=	(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2 <i>H</i> -3,1-benzoxazin-2-one
EMCV	=	Encephalomyocarditis virus
FDA	=	Food and Drug Administration
GA	=	Genetic algorithm
Glu (E)	=	Glutamic acid

Gly (G)	=	Glycine
HBV-097	=	(s)-4-isopropoxycarbonyl-6-methoxy-3-methylthio- methyl-3,4-dihydroquinixalin-2-(1H)-thione
His (H)	=	Histidine
HIV-1	=	human immunodeficiency virus type-1
HF	=	Hartree-Fock
Ile (I)	=	Isoleucine
LCAO	=	Linear combination of atomic orbitals
Leu (L)	=	Leucine
Lys (K)	=	Lysine
MCSCF	=	Multi-Configuration SCF
MOT	=	Molecular orbital theory
MP2	=	The second-order Møller-Plesset calculation
MPPT	=	Møller-Plesset perturbation theory
MSC-194	=	1-[2-(3-acetyl-2-hydroxy-6-methoxy-phenyl)- cyclopropyl]-3-(5-cyano-pyridin-2-yl)-thiourea
Nevirapine	=	11-cyclopropyl-5,11-dihydro-4-methyl-6H- dipyrido[3,2-b:2',3'-f][1,4]diazepin-6-one
NMR	=	Nuclear magnetic resonance
NNRTIs	=	Non-nucleoside reverse transcriptase inhibitors
NRTIs	=	Nucleoside reverse transcriptase inhibitors
p51	=	Peptide having molecular weight 51 kilodalton
p66	=	Peptide having molecular weight 66 kilodalton
PCR	=	Polymerase chain reaction
PETT	=	Phenylethylthiazolylthiourea
Phe (F)	=	Phenylalanine
PIs	=	Protease inhibitors
PNU-142721	=	6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)- pyrimidin-4-ylamine
Pro (P)	=	Proline
QM	=	Quantum mechanics

RCSB PDB	=	The research collaboratory for structural bioinformatics (RCSB), the non-profit consortium that manages the Protein Data Bank (PDB)
RNA	=	RiboNucleic Acid
RNaseH	=	Ribonuclease H
RT	=	Reverse transcriptase
S-1153	=	5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1H-imidazol-2-yl-methylcarbamate
SCF	=	Self-consistent field method
Ser (S)	=	Serine
STOs	=	Slater-type orbitals
Thr (T)	=	Threonine
Trp (W)	=	Tryptophan
Tyr (Y)	=	Tyrosine
UC-781	=	N-[4-chloro-3-[(1,1-dimethylethoxy)imino]phenyl]-2-methyl-3-furan-carbothiamide
Val (V)	=	Valine